Immunocore (NASDAQ: IMCR) revenue
Immunocore reported revenue of $400.0m for fiscal 2025, 29.0% more than in fiscal 2024 ($310.2m). Since fiscal 2022 its revenue has grown by 129.4%, an average growth of 31.9% a year.
Immunocore has grown its revenue for 3 years in a row, and fiscal 2025 is the highest of its 4 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $400.0m | +29.0% | −$45.4m | −11.3% |
| 2024 | $310.2m | +24.4% | −$70.5m | −22.7% |
| 2023 | $249.4m | +43.1% | −$59.6m | −23.9% |
| 2022 | $174.4m | — | −$51.7m | −29.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Immunocore revenue compared with its sector
By revenue for its latest fiscal year, Immunocore ranks 205th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Immunocore, 29.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 203rd | Innoviva | $411.3m | 14.7% |
| 204th | Ardelyx | $407.3m | 22.1% |
| 205th | Immunocore | $400.0m | 29.0% |
| 206th | Krystal Biotech | $389.1m | 33.9% |
| 207th | Sonida Senior Living | $381.1m | 25.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Immunocore
- How much revenue did Immunocore make in fiscal 2025?
- Immunocore reported revenue of $400.0m for fiscal 2025, compared with $310.2m in fiscal 2024.
- How much has the revenue of Immunocore grown?
- Between fiscal 2022 and fiscal 2025 it went from $174.4m to $400.0m: 129.4% more, an average growth of 31.9% a year.
- What was the best year for revenue at Immunocore?
- Of its last 4 fiscal years, fiscal 2025, with $400.0m.
- Where does Immunocore rank in its sector by revenue?
- It ranks 205th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Immunocore come from?
- From the annual report (Form 10-K) that Immunocore files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Immunocore files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Immunocore: the Immunocore page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.